Cat No:LP000390
Product Name:SNS-062
CAS#1270014-40-8
SNS-062 inhibits pBTK in human whole blood with an average IC50 of 50 nM. SNS-062 inhibits WT and C481S BTK with similar IC50s (pBTK IC50s: WT BTK 2.9 nM, C481S BTK 4.4 nM)[1]. In a recombinant kinase assay, IC50s of SNS-062 against WT BTK and C481S BTK are 4.6 nM and 1.1 nM. SNS-062 retains activity against the mutated BTK variant. SNS-062 is six times more potent than ibrutinib and greater than 640 times more potent than acalabrutinib against C481S BTK. SNS-062 demonstrates dose-dependent inhibition of BTK in primary patient CLL cells comparable to ibrutinib via immunoblot for BTK phosphorylation. SNS-062 decreases viability of primary CLL cells in the presence of HS5 stromal protection by 5.5%.
